GlobalData on MSN3d
SkylineDx study highlights value in combined myeloma diagnostic approach
SkylineDx’s SKY92 test with fluorescence in situ hybridisation testing led to more accurate identification of high-risk ...
Finanznachrichten6d
SKYLINEDX ANNOUNCES NEW PUBLICATION ON SKY92 GENE EXPRESSION PROFILING TEST in DEFINING ULTRA-HIGH-RISK MULTIPLE MYELOMA
ROTTERDAM, the Netherlands and SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for ...
Medical Device Network3d
SkylineDx study highlights value in combined myeloma diagnostic approach
Image credit: OGphoto via Getty Images. SkylineDx has published a new study marking a “significant advancement” in the understanding and identification of high-risk (HR) multiple myeloma (MM) patients ...
Frontiers24d
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
TA reports institutional grants from SkylineDx, institutional grants and personal fees from Novartis, institutional grants from NeraCare, personal fees from BMS, institutional grants from Sanofi, ...
WFMZ-TV16d
Teenagers who think they’re fat more likely to consider self-harm: study
Teenagers who perceive themselves as overweight are three times more likely to consider self-harming, warns new research. The heightened risk is present regardless of whether the youngster is ...
WFMZ-TV15d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
BioSpace8d
U.S. Blood Cancer Diagnostics Market Size to Hit USD 9,276 Million by 2034
According to Statifacts, the U.S. blood cancer diagnostics market size is calculated at USD 5,046 million in 2025 and is expected to reach around USD 9,276 million by 2034, growing at a CAGR of 7% for ...